Anxiogenic effects of cocaine withdrawal in zebrafish

Physiology and Behavior

Volumn 93, Issue 1-2, 2008, Pages 160-171

  López Patiño, Marcos A ^a   Yu, Lili ^a   Cabral, Howard ^b   Zhdanova, Irina V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Anxiety; Benzodiazepine; Cocaine; Locomotor activity; Withdrawal; Zebrafish

Indexed keywords

ANXIOLYTIC AGENT; COCAINE; DIAZEPAM; DOPAMINE UPTAKE INHIBITOR;

ANALYSIS OF VARIANCE; ANIMAL; ANXIETY; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; HYPERKINESIA; MALE; MOTOR ACTIVITY; NONPARAMETRIC TEST; STEREOTYPY; TIME; WITHDRAWAL SYNDROME; ZEBRA FISH;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; COCAINE; DIAZEPAM; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; MALE; MOTOR ACTIVITY; STATISTICS, NONPARAMETRIC; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; ZEBRAFISH;

EID: 42449158661     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2007.08.013     Document Type: Article

References (49)

1. Rizkalla C, Sue YJ. Cocaine. Pediatr Rev 2006;27(11):436-8.
2. American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. fourth ed. Washinghton, DC: American Psychiatric association; 1994.
3. BradberryCW.Cocaine sensitization and dopaminemediation of cue effects in rodents, monkeys, and humans: areas of agreement, disagreement, and implications for addiction. Psychopharmacology (Berl) 2007;191(3):705-17.
4. Faganello FR, Mattioli R. Anxiolytic-like effect of Chlorpheniramine in inhibitory avoidance in goldfish submitted to telencephalic ablation. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):269-74.
5. Pich EM, Epping-Jordan MP. Transgenic mice in drug dependence research. Ann Med 1998;30(4):390-6.
6. Wolf FW, Heberlein U. Invertebrate models of drug abuse. J Neurobiol 2003;54(1):161-78.
7. Darland T, Dowling JE. Behavioral screening for cocaine sensitivity in mutagenized zebrafish. PNAS 2001;98:11691-6.
8. Gerlai R, Lahav M, Guo S, Rosenthal A. Drinks like a fish: zebra fish (Danio rerio) as a behavior genetic model to study alcohol effects. Pharmacol Biochem Behav 2000;67:773-82.
9. Levin ED, Chen E. Nicotinic involvement in memory function in zebrafish. Neurotoxicol Teratol 2004;26(6):731-5.
10. Ninkovic J, Folchert A, Makhankov YV, Neuhauss SCF, Sillaber I, StraehleW, et al. Genetic identification of AChE as a positive modulator of addiction to the psychostimulant D-amphetamine in zebrafish. J Neurobiol 2006;66:463-75.
11. Immelmann K, Beer C. A dictionary of ethology. London: Harvard University Press; 1989.
12. Schuelke GS, Terry LC, Powers RH, Rice J, Madden JA. Cocaine analgesia: an in vivo structure-activity study. Pharmacol Biochem Behav 1996;53:133-40.
13. Lin SN, Moody DE, Bigelow GE, Foltz RF. A validated liquid chromatography-atmospheric pressure on chemical ionization-tandem mass spectrometry method for the quantitation of cocaine and benzylecgonine in human plasma. J Anal Toxicol 2001;25:497-503.
14. Nayomchai T, Akhavan A, Festa ED, Lin SN, Lamn L, Foltz R, et al. Estrogen and progesterone affect cocaine pharmacokinetics in female rats. Brain Res Bull 2006;68:310-4.
15. Peitsaro N, Kaslin J, Anichtchik OV, Panula P. Modulation of the histaminergic system and behaviour by alpha-fluoromethylhistidine in zebrafish. J Neurochem 2003;86:432-41.
16. Birnbaum SG, Podell DM, Arnsten AF. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav 2000;67(3):397-403.
17. Dorow R, Horowski R, Paschelke G, Amin M. Severe anxiety induced by FG7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 1983;2:98-9.
18. Nishimura Y, Yoshida M, Watanabe S. The effect on other individual presentations of the goldfish by FG7142 injection. Jpn J Psychopharmacol 2002;22(2):55-9.
19. Takamatsu H, Noda A, Kurumaji A,Murakami Y, TatsumiM, Ichise R, et al. APETstudy following treatmentwith a pharmacological stressor, FG7142, in conscious rhesus monkeys. Brain Res 2003;980(2):275-80.
20. Singewald N. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci Biobehav Rev 2007;31:18-40.
21. Anthony JC, Tien AY, Petronis KR. Epidemiologic evidence on cocaine use and panic attacks. Am J Epidemiol 1989;129:543-9.
22. Blanchard DC, Blanchard RJ. Cocaine potentiates defensive behaviors related to fear and anxiety. Neurosci Biobehav Rev 1999;23:981-99.
23. Crowley TJ, Mikulich SK, Williams EA, Zerbe GO, Ingersoll NC. Cocaine, social behavior, and alcohol-solution drinking in monkeys. Drug Alcohol Depend 1992;29(3):205-23.
24. De Souza Silva MA, Mello Jr EL, Muller CP, Jocham G, Maior RS, Huston JP, et al. Interaction of the tachykinin NK3 receptor agonist senktide with behavioral effects of cocaine in marmosets (Callithrix penicillata). Peptides 2006;27:2214-23.
25. Ettenberg A, Geist TD. Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology (Berl) 1991;103 (4):455-61.
26. Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987;83:841-6.
27. Moldow RL, Fischman AJ. Cocaine induced secretion of ACTH, betaendorphin, and corticosterone. Peptides 1987;8(5):819-22.
28. Rivier C, Vale W. Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain Res 1987;422(2):403-6.
29. Sarnyai Z. Oxytocin and neuroadaptation to cocaine. Prog Brain Res 1998;119:449-66.
30. Stanek LM. Cocaine-and amphetamine related transcript (CART) and anxiety. Peptides 2006;27(8):2005-11.
31. Yang XM, Gorman AL, Dunn AJ, Goeders NE. Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol Biochem Behav 1992;41:643-50.
32. Markou A, Koob GF. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 1991;4(1):17-26.
33. Pollandt S, Liu J, Orozco-Cabal L, Grigoriadis DE, Vale WW, Gallagher JP, et al. Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA. Eur J Neurosci 2006;24(6):1733-43.
34. Bang PI, Yelick PC, Malicki JJ, Sewell WF. High-throughput behavioral screening method for detecting auditory response defects in zebrafish. J Neurosci Methods 2002;118(2):177-87.
35. Levin ED, Bencan Z, Cerutti DT. Anxiolytic effects of nicotine in zebrafish. Physiol Behav 2007;90:54-8.
36. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, Fratta W. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 2007;53(1):1-16.
37. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Tatgets CNS Neurol Disord 2004;4: 633-42.
38. Carey RJ, Damianopoulos E. Cocaine conditioning and sensitization: the habituation factor. Pharmacol Biochem Behav 2006;84(1):128-33.
39. Carey RJ, De Palma G, Damianopoulos E. Acute and chronic behavioral effects in novel versus familiar environments: open-field familiarity differentiates cocaine locomotor stimulant effects from cocaine emotional behavioral effects. Behav Brain Res 2005;158:321-30.
40. Kiyatkin EA. State-dependent peculiarities of cocaine-induced behavioral sensitization and their possible reasons. Int J Neurosci 1992;67:93-103.
41. Mattingly BA, Himmler C, Bonta T, Rice LL. Effects of selective dopamine D1 and D2 type receptor antagonists on the development of behavioral sensitization to 7-OH-DPAT. Psychopharmacology 1998;140: 387-97.
42. Chiang WK, Goldfrank LR. Substance withdrawal. EmergMed Clin North Am 1990;8(3):613-31.
43. Paine TA, Jackman SL, Olmstead MC. Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 2002;13(7):511-23.
44. Kudryavtseva NN, Gerrits MA, Alekseenko OV, Van Ree JM. Chronic cocaine injections attenuate behavioral response of kappa-opioid receptors to U-50,488H agonist. Bull Exp Biol Med 2005;140(3):320-2.
45. Dews PB,Wenger GR. In: Thompson T, Dews PB, editors. Rate-dependency of the behavioral effects of amphetamine. Advances in Behavioral Pharmacology. New York: Academic Press; 1977. p. 167-227.
46. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-defficithyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-52.
47. Solanto MV. Dopamine disfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 2002;130:65-71.
48. Isaac W, Troelstrup R. Opposite effect of illumination and d-amphetamine upon activity in the squirrel monkey (Saimiri) and owl monkey (Aotes). Psychopharmacoloy 1969;15:260-4.
49. Kallman WM, Isaac W. The effects of age and illumination on the doseresponse curves for three stimulants. Psychopharmacology 1975;40:313-8.